Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
Not establishedNo board position is currently listed on this profile
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Mr. Pinion has served as Chief Quality Officer and Executive Vice President of Translational Sciences since September 2017, with prior roles at Genentech from 2005 to 2015 including SVP and Global Head of Quality and Compliance for Roche/Genentech Pharma Technical Operations. He holds a B.S. in Mechanical Engineering from the University of West Virginia.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Connections

Explore the roles, education and affiliations published in this record.

Ultragenyx Pharmaceutical Inc.

Open Ultragenyx Pharmaceutical Inc. profile →

Chief Quality Officer and Executive Vice President of Translational Sciences at Ultragenyx Pharmaceutical Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-17

Ultragenyx Pharmac…Ultragenyx Pharmaceutical Inc.John R. Pinion II

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingRARE DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:john-r-pinion-ii
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive company · Source reportedExecutive at Ultragenyx Pharmaceutical Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: Chief Quality Officer and Executive Vice President of Translational Sciences1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

View all sources2 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1515673/000130817926000174/lrare2026_def14a.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 12, 2026

    Supports: Chief Quality Officer and Executive Vice President of Translational Sciences at Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)